JP2023116498A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023116498A5 JP2023116498A5 JP2023084640A JP2023084640A JP2023116498A5 JP 2023116498 A5 JP2023116498 A5 JP 2023116498A5 JP 2023084640 A JP2023084640 A JP 2023084640A JP 2023084640 A JP2023084640 A JP 2023084640A JP 2023116498 A5 JP2023116498 A5 JP 2023116498A5
- Authority
- JP
- Japan
- Prior art keywords
- aqueous pharmaceutical
- pharmaceutical formulation
- dexamethasone
- less
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 11
- 229960003957 dexamethasone Drugs 0.000 claims 9
- 238000009472 formulation Methods 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 239000003755 preservative agent Substances 0.000 claims 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 239000002738 chelating agent Substances 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 230000002335 preservative effect Effects 0.000 claims 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 2
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 claims 2
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 claims 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical group [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims 2
- 230000000087 stabilizing effect Effects 0.000 claims 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims 1
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 claims 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims 1
- 229960001950 benzethonium chloride Drugs 0.000 claims 1
- 229940109239 creatinine Drugs 0.000 claims 1
- 229960003657 dexamethasone acetate Drugs 0.000 claims 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims 1
- 229940001584 sodium metabisulfite Drugs 0.000 claims 1
- 235000010262 sodium metabisulphite Nutrition 0.000 claims 1
- 235000010265 sodium sulphite Nutrition 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862767448P | 2018-11-14 | 2018-11-14 | |
| US62/767,448 | 2018-11-14 | ||
| JP2020529561A JP7337060B2 (ja) | 2018-11-14 | 2019-11-14 | 安定なグルココルチコイド製剤 |
| PCT/US2019/061363 WO2020102474A1 (en) | 2018-11-14 | 2019-11-14 | Stable glucocorticoid formulation |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020529561A Division JP7337060B2 (ja) | 2018-11-14 | 2019-11-14 | 安定なグルココルチコイド製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023116498A JP2023116498A (ja) | 2023-08-22 |
| JP2023116498A5 true JP2023116498A5 (https=) | 2023-11-17 |
Family
ID=68808595
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020529561A Active JP7337060B2 (ja) | 2018-11-14 | 2019-11-14 | 安定なグルココルチコイド製剤 |
| JP2023084640A Pending JP2023116498A (ja) | 2018-11-14 | 2023-05-23 | 安定なグルココルチコイド製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020529561A Active JP7337060B2 (ja) | 2018-11-14 | 2019-11-14 | 安定なグルココルチコイド製剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200289650A1 (https=) |
| EP (1) | EP3706721A1 (https=) |
| JP (2) | JP7337060B2 (https=) |
| KR (2) | KR20220130253A (https=) |
| CN (1) | CN111918645A (https=) |
| AU (1) | AU2019378874B2 (https=) |
| BR (1) | BR112021009365A2 (https=) |
| CA (1) | CA3118505A1 (https=) |
| EA (1) | EA202191345A1 (https=) |
| IL (1) | IL283199A (https=) |
| MX (1) | MX2021005665A (https=) |
| SG (1) | SG11202104702VA (https=) |
| WO (1) | WO2020102474A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12609718B2 (en) | 2023-06-14 | 2026-04-21 | Hewlett Packard Enterprise Development Lp | WiFi-7 optimized split band architecture and method of operation |
| CN116789728B (zh) * | 2023-06-16 | 2026-02-06 | 山东斯瑞药业有限公司 | 一种降低糖皮质激素原料药重金属元素杂质含量的工艺 |
| CN116807970A (zh) * | 2023-07-26 | 2023-09-29 | 遂成药业股份有限公司 | 一种地塞米松磷酸钠注射液及其制备方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136607A (en) * | 1995-11-02 | 2000-10-24 | Bayer Corporation | Multi-analyte reference solutions with stable pO2 in zero headspace containers |
| US20040197333A1 (en) * | 2000-02-10 | 2004-10-07 | Cornell Research Foundation, Inc. | Use of TGF-beta antagonists to inhibit tumor cell formation or progression |
| US9694103B2 (en) * | 2003-04-16 | 2017-07-04 | The Children's Hospital Of Philadelphia | Photochemical activation of surfaces for attaching biomaterial |
| WO2005110374A1 (en) * | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
| US20080038316A1 (en) * | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
| JP4598484B2 (ja) * | 2004-11-11 | 2010-12-15 | テルモ株式会社 | 塩酸リトドリン注射液製剤 |
| KR101121529B1 (ko) * | 2005-12-22 | 2012-02-28 | 코와 가부시키가이샤 | 스테로이드의 경시적 안정성이 개선된 외용 제제 |
| AU2013200089B2 (en) * | 2006-02-09 | 2016-03-03 | Santen Pharmaceutical Co., Ltd | Stable formulations, and methods of their preparation and use |
| EP2249801A2 (en) * | 2008-02-07 | 2010-11-17 | Amgen Inc. | Stabilized protein compositions |
| CN101623291B (zh) | 2008-07-07 | 2011-12-07 | 天津金耀集团有限公司 | 一种地塞米松磷酸钠注射液 |
| EP2365812A4 (en) * | 2008-11-10 | 2012-05-16 | Nitric Biotherapeutics Inc | PHARMACEUTICAL FORMULATIONS FOR THE IONTOPHORETIC DELIVERY OF A CORTICOSTEROID |
| JP2011136973A (ja) * | 2009-12-28 | 2011-07-14 | Keiki Imoto | 安定なエダラボン含有水性製剤 |
| GB2477545B (en) * | 2010-02-05 | 2011-12-21 | Special Products Ltd | A liquid morphine composition for buccal administration |
| NZ607906A (en) | 2010-08-18 | 2015-11-27 | Theresa Deisher | Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues |
| ITMI20122002A1 (it) | 2012-11-26 | 2014-05-27 | Farmacologico Milanese Srl Lab | Preparazioni farmaceutiche liquide stabilizzate |
| JP6741286B2 (ja) * | 2013-03-28 | 2020-08-19 | テルモ株式会社 | 包装されたアセトアミノフェン注射液製剤の製造方法 |
| KR101485243B1 (ko) * | 2013-05-08 | 2015-01-21 | 씨제이헬스케어 주식회사 | 안정화된 페메트렉시드 제제 |
| GR1008921B (el) | 2015-12-10 | 2017-01-12 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση περιεχον δεξαμεθαζονη |
| EP3490605B1 (en) * | 2017-04-01 | 2023-06-07 | AVM Biotechnology, LLC | Replacement of cytotoxic preconditioning before cellular immunotherapy |
| CN107375200A (zh) | 2017-06-16 | 2017-11-24 | 北京立时达药业有限公司 | 一种地塞米松磷酸钠注射液及其制备方法 |
| EP3488851A1 (en) * | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
-
2019
- 2019-11-14 JP JP2020529561A patent/JP7337060B2/ja active Active
- 2019-11-14 EA EA202191345A patent/EA202191345A1/ru unknown
- 2019-11-14 CA CA3118505A patent/CA3118505A1/en active Pending
- 2019-11-14 EP EP19817060.7A patent/EP3706721A1/en active Pending
- 2019-11-14 CN CN201980007393.XA patent/CN111918645A/zh active Pending
- 2019-11-14 MX MX2021005665A patent/MX2021005665A/es unknown
- 2019-11-14 WO PCT/US2019/061363 patent/WO2020102474A1/en not_active Ceased
- 2019-11-14 KR KR1020227031562A patent/KR20220130253A/ko not_active Ceased
- 2019-11-14 KR KR1020207017795A patent/KR102444113B1/ko active Active
- 2019-11-14 SG SG11202104702VA patent/SG11202104702VA/en unknown
- 2019-11-14 AU AU2019378874A patent/AU2019378874B2/en active Active
- 2019-11-14 BR BR112021009365-6A patent/BR112021009365A2/pt unknown
-
2020
- 2020-05-28 US US16/885,815 patent/US20200289650A1/en active Pending
-
2021
- 2021-05-13 IL IL283199A patent/IL283199A/en unknown
-
2023
- 2023-05-23 JP JP2023084640A patent/JP2023116498A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023116498A5 (https=) | ||
| CN102985071B (zh) | 透析前体组合物 | |
| US3970750A (en) | Effervescent potassium chloride composition | |
| US2795529A (en) | Stabilized hyaluronidase solution containing calcium chloride | |
| US8691802B2 (en) | Stabilized compositions comprising a therapeutically active agent and an oxidizing preservative | |
| CN103796634B (zh) | 透析前体组合物 | |
| CN103747789B (zh) | 透析前体组合物 | |
| JP2025163108A5 (https=) | ||
| JP2009521521A5 (https=) | ||
| CN102946886A (zh) | 透析前体组合物 | |
| JP2008542237A5 (https=) | ||
| SI21026B (sl) | Stabilen, nasalno, oralno ali sublingvalno uporabljiv farmacevtski pripravek | |
| ES2224917T1 (es) | Composiciones farmaceuticas de agente fibrinolitico. | |
| JP2009521473A5 (https=) | ||
| JP2021529763A5 (https=) | ||
| JP2006512286A5 (https=) | ||
| JP2021513521A5 (https=) | ||
| CO5570681A2 (es) | Formulaciones de jarabe de ribavirina | |
| PT90356B (pt) | Processo para a preparacao de composicoes farmaceuticas contendo solucoes aquosas de pentamidina | |
| RU96109524A (ru) | Композиция - лекарственная форма противоартрозного средства глюкозамина гидрохлорида для иньекций | |
| JP4956981B2 (ja) | オキシメタゾリン含有水性組成物 | |
| US8853265B2 (en) | Oral composition to reduce cold symptoms and duration of same | |
| JP4806956B2 (ja) | 点眼用液剤 | |
| CN115137699A (zh) | 一种增效防腐的右美托咪定鼻喷剂 | |
| JP5111372B2 (ja) | 安定および保存化ケトチフェン眼用組成物 |